资源 » 参考数据库 » 客户发表文献

至今，GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次，处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果，再次证明GenScript 有能力帮助业内科学家Make research easy.

A Phase 1 Dose Escalation Trial of BN-CV301， a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules.

Clin. Cancer Res.. 2019-05;

Gatti-MaysMargaret E，StraussJulius，DonahueRenee N，PalenaClaudia，Del RiveroJaydira，RedmanJason M，MadanRavi A，MarteJennifer L，CordesLisa M，LampingElizabeth，OrpiaAlavin，BurmeisterAndrea，WagnerEva，Pico NavarroCesar，HeeryChristopher R，SchlomJeffrey，GulleyJam

Products/Services Used	Details	Operation
Peptide Synthesis	… cytomegalovirus, Epstein-Barr virus, influenza and tetanus toxin) served as negative and positive 257 controls, respectively. Peptide mixes were purchased from JPT (Berlin, Germany) and GenScript 258 (Piscataway, NJ), reconstituted in DMSO, and used immediately. 259 …	Get A Quote

摘要

BN-CV301 is a poxviral-based vaccine comprised of recombinant (rec.) Modified vaccinia Ankara (MVA-BN-CV301; prime) and rec. fowlpox (FPV-CV301; boost). Like its predecessor PANVAC， BN-CV301 contains transgenes encoding tumor-associated antigens， MUC1 and CEA， as well as costimulatory molecules (B7.1， ICAM-1， LFA-3). PANVAC was re-engineered to make it safer and more antigenic.